Randomized trial · people
Tirzepatide: AHI fell 25.3 and 29.3 events per hour in SURMOUNT-OSA
Checked against the paper Randomized trialPublished by PepVault
The takeaway
For people with obesity and moderate-to-severe sleep apnea, this pair of trials found tirzepatide cut breathing events during sleep well beyond placebo, whether or not they used a PAP machine, with mostly mild to moderate stomach-related side effects.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2024
- Journal
- N Engl J Med
What they tested
The team tested whether tirzepatide could ease moderate-to-severe obstructive sleep apnea, where breathing stops and starts during sleep, in adults with obesity.
How the study was done
Two phase 3, double-blind, randomized, placebo-controlled trials in adults with moderate-to-severe obstructive sleep apnea and obesity: trial 1 enrolled people not using positive airway pressure (PAP, a breathing machine worn at night) and trial 2 enrolled people already using it. Participants got the highest dose they could tolerate (10 mg or 15 mg) or placebo, a dummy treatment, for 52 weeks.

Model. Individual results vary.
What they found
The main measure was the apnea-hypopnea index (AHI, the number of times breathing stops or gets shallow per hour of sleep), which started at an average of 51.5 in trial 1 and 49.5 in trial 2. At week 52 in trial 1, AHI dropped by 25.3 events per hour with tirzepatide versus 5.3 with placebo, a difference of 20.0 (P<0.001). In trial 2, it dropped by 29.3 with tirzepatide versus 5.5 with placebo, a difference of 23.8 (P<0.001). Tirzepatide also beat placebo on all key secondary measures, including body weight, hypoxic burden (how low oxygen falls during sleep), hsCRP (a marker of inflammation), systolic blood pressure and patients' own reports of sleep.
What it doesn’t show
The trials ran for 52 weeks, so they don't show what happens over a longer period or after stopping the drug. The work was funded by Eli Lilly.
The paper
Malhotra et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024.
The compound
More studies on Tirzepatide
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeksRandomized trial · people · 2025
- Every study on Tirzepatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.